Discover
KALV
KalVista Pharmaceuticals, Inc.
27.00
2 x 19.43
2 x 34.54
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 67.18% | |
| 1y | 106.26% |
day range
9.83
52 week range
27.00
| Open | Prev Close | 27.00 | Low | High | Mkt Cap | 1.44B | |||
| Vol | 0.00 | Avg Vol | 3.63M | EPS | -3.94 | P/E | -6.85 | Forward P/E | 25.45 |
| Beta | -0.12 | Short Ratio | 0.94 | Inst. Own | 136.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 24.43 | 200-d Avg | 17.09 | 1yr Est | 27.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-13 | 2026-07 | -0.29 | N/A | N/A | N/A |
| 2026-05-15 | 2025-12 | -0.38 | -0.92 | -0.54 | -144.52% |
| 2026-03-24 | 2026-03 | -0.54 | -1.01 | -0.47 | -87.04% |
| 2025-11-10 | 2025-09 | -0.96 | -0.92 | 0.04 | 4.17% |
| 2025-09-11 | 2025-07 | -0.91 | -1.12 | -0.21 | -23.08% |
| 2025-07-10 | 2025-04 | -0.8 | -0.99 | -0.19 | -23.92% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-01 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2026-04-30 | Needham | Downgrade | Buy | Hold |
| 2026-03-26 | Stifel | Upgrade | Buy | Buy |
| 2026-03-26 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-03-25 | Needham | Upgrade | Buy | Buy |
| 2026-01-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-25 | AUDHYA PAUL K | Officer | 150.26K | Sale |
| 2026-05-21 | PALLEIKO BENJAMIN L | Chief Executive Officer | 479.99K | Sale |
| 2026-05-21 | PIEKOS BRIAN | Chief Financial Officer | 21.66K | Sale |
| 2026-05-25 | SWEENY NICOLE | Officer | 59.29K | Sale |
| 2026-03-25 | VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-05-26 | YEA CHRISTOPHER M | Officer | 229.92K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VR Adviser, LLC | 6.47M | 0.00 | 12.16% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 4.96M | 0.00 | 9.32% |
| 2026-03-30 | Suvretta Capital Management, LLC | 4.77M | 0.00 | 8.96% |
| 2026-03-30 | TANG CAPITAL MANAGEMENT LLC | 4.57M | 0.00 | 8.59% |
| 2026-03-30 | BlackRock Inc | 3.80M | 0.00 | 7.13% |
| 2026-03-30 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.88M | 0.00 | 5.40% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | American Funds SMALLCAP World A | 2.81M | 0.00 | 5.28% |
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 1.35M | 0.00 | 2.54% |
| 2026-05-30 | State Street® SPDR® S&P® Biotech ETF | 1.19M | 0.00 | 2.24% |
| 2026-05-28 | iShares Russell 2000 ETF | 914.71K | 0.00 | 1.72% |
| 2026-04-29 | MEDICAL BioHealth EUR Acc | 861.55K | 0.00 | 1.62% |
| 2026-04-29 | apo Medical Opportunities R | 771.44K | 0.00 | 1.45% |
Split
| Split | Date |
|---|---|
| 1 : 14 | 2016-11-22 |
| 1 : 14 | 2016-11-21 |